These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 34980495)
21. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring. Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985 [TBL] [Abstract][Full Text] [Related]
22. Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS. Kim KP; Parise RA; Holleran JL; Lewis LD; Appleman L; van Erp N; Morris MJ; Beumer JH J Pharm Biomed Anal; 2017 May; 138():197-205. PubMed ID: 28219796 [TBL] [Abstract][Full Text] [Related]
23. Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Nakabayashi M; Xie W; Buckle G; Bubley G; Ernstoff MS; Walsh W; Morganstern DE; Kantoff PW; Taplin ME Urology; 2013 Mar; 81(3):611-6. PubMed ID: 23452809 [TBL] [Abstract][Full Text] [Related]
24. The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer. Shah NJ; Patel VG; Zhong X; Pina L; Hawley JE; Lin E; Gartrell BA; Febles VA; Wise DR; Qin Q; Mellgard G; Joshi H; Nauseef JT; Green DA; Vlachostergios PJ; Kwon DH; Huang F; Liaw B; Tagawa S; Kantoff P; Morris MJ; Oh WK JNCI Cancer Spectr; 2022 May; 6(3):. PubMed ID: 35657341 [TBL] [Abstract][Full Text] [Related]
25. Combined androgen blockade: the case for bicalutamide. Klotz L; Schellhammer P Clin Prostate Cancer; 2005 Mar; 3(4):215-9. PubMed ID: 15882477 [TBL] [Abstract][Full Text] [Related]
26. Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide. Haas NB; LaRiviere MJ; Buckingham TH; Cherkas Y; Calara-Nielsen K; Foulk B; Patel J; Gross S; Smirnov D; Vaughn DJ; Amaravadi R; Wellen KE; Savitch SL; Majmundar KJ; Black TA; Yee SS; He M; Min EJ; Long Q; Jones JO; Pal SK; Carpenter EL Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):448-456. PubMed ID: 33009489 [TBL] [Abstract][Full Text] [Related]
27. Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy. Carpenter V; Saleh T; Min Lee S; Murray G; Reed J; Souers A; Faber AC; Harada H; Gewirtz DA Biochem Pharmacol; 2021 Nov; 193():114765. PubMed ID: 34536356 [TBL] [Abstract][Full Text] [Related]
28. Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285-93: Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients. Wambier CG; Nau GJ Eur Urol; 2022 Jun; 81(6):e141-e142. PubMed ID: 35304000 [No Abstract] [Full Text] [Related]
29. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136 [TBL] [Abstract][Full Text] [Related]
32. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses. Armstrong AJ; Shore ND; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Gomez-Veiga F; Rosbrook B; Lee HJ; Haas GP; Stenzl A J Urol; 2021 May; 205(5):1361-1371. PubMed ID: 33356529 [TBL] [Abstract][Full Text] [Related]
33. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Gucalp A; Tolaney S; Isakoff SJ; Ingle JN; Liu MC; Carey LA; Blackwell K; Rugo H; Nabell L; Forero A; Stearns V; Doane AS; Danso M; Moynahan ME; Momen LF; Gonzalez JM; Akhtar A; Giri DD; Patil S; Feigin KN; Hudis CA; Traina TA; Clin Cancer Res; 2013 Oct; 19(19):5505-12. PubMed ID: 23965901 [TBL] [Abstract][Full Text] [Related]
34. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
35. The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells. Leach DA; Mohr A; Giotis ES; Cil E; Isac AM; Yates LL; Barclay WS; Zwacka RM; Bevan CL; Brooke GN Nat Commun; 2021 Jul; 12(1):4068. PubMed ID: 34210968 [TBL] [Abstract][Full Text] [Related]
36. Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis. Fallara G; Belladelli F; Robesti D; Raggi D; Nocera L; Marandino L; Galsky MD; Montorsi F; Malavaud B; Ploussard G; Necchi A; Martini A Crit Rev Oncol Hematol; 2022 Nov; 179():103801. PubMed ID: 36031173 [TBL] [Abstract][Full Text] [Related]
37. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk. Azad AA; Armstrong AJ; Alcaraz A; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Alekseev B; Iguchi T; Shore ND; Gomez-Veiga F; Rosbrook B; Lee HJ; Haas GP; Stenzl A Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):274-282. PubMed ID: 34420037 [TBL] [Abstract][Full Text] [Related]
38. Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less. Parekh A; Chen MH; Graham P; Mahal BA; Hirsch AE; Nakabayashi M; Evan C; Kantoff PW; Martin NE; Nguyen PL Clin Genitourin Cancer; 2015 Feb; 13(1):e1-6. PubMed ID: 25103271 [TBL] [Abstract][Full Text] [Related]
39. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines. Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490 [TBL] [Abstract][Full Text] [Related]
40. Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. Sweeney CJ; Martin AJ; Stockler MR; Begbie S; Chi KN; Chowdhury S; Coskinas X; Frydenberg M; Hague WE; Horvath LG; Joshua AM; Lawrence NJ; Marx GM; McCaffrey J; McDermott R; McJannett M; North SA; Parnis F; Parulekar W; Pook DW; Reaume MN; Sandhu SK; Tan A; Tan TH; Thomson A; Tu E; Vera-Badillo F; Williams SG; Yip S; Zhang AY; Zielinski RR; Davis ID; Eur Urol; 2021 Sep; 80(3):275-279. PubMed ID: 34030924 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]